Alector Reports Third Quarter 2026 Financial Results and Provides Business Update
Key Highlights
- ➤Collaboration revenue $162.9 million, up from $3.3 million year over year
- ➤Net income $124.6 million, or $1.11 per share, versus $34.7 million loss
- ➤Genentech license includes $100 million upfront and up to $1.17 billion milestones
- ➤AL137 targets first-in-human dosing no later than April 2027
- ➤Cash, license proceeds, and offering expected to fund operations into second half of 2029
Expert Statements
Arnon Rosenthal, Chief Executive Officer of Alector
“Since our last quarterly update, we exclusively licensed AL050 to Genentech, strengthened our balance sheet, and moved our wholly owned programs closer to the clinic.”
Arnon Rosenthal, Chief Executive Officer of Alector
“The Alector Brain Carrier is designed to address one of the central challenges in treating neurodegenerative disease: delivering enough drug to the brain.”
Arnon Rosenthal, Chief Executive Officer of Alector
“With AL137 targeting first-in-human dosing no later than April 2027, and AL164 and AL062 targeting first-in-human studies in Q2 2028, we are advancing toward multiple clinical readouts as we work to bring new options to patients with neurodegenerative diseases.”
Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD), targeting first-in-human dosing in Australia no later than April 2027.
Continued progress across AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL062 (ABC-enabled alpha-synuclein siRNA for Parkinson's disease (PD) and Lewy body dementia (LBD)), each targeting first-in-human studies in Q2 2028.
Get started
Create a free account to read the full story.